At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VCYT Veracyte
Market Closed 06-28 16:00:00 EDT
21.67
-0.32
-1.46%
盘后21.67
+0.000.00%
19:00 EDT
High22.12
Low21.13
Vol1.63M
Open22.10
D1 Closing21.99
Amplitude4.50%
Mkt Cap1.66B
Tradable Cap1.65B
Total Shares76.45M
T/O35.28M
T/O Rate2.15%
Tradable Shares76.07M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
3 Medical Instruments Picks to Navigate Industry Challenges
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.